Published in Virol J on March 03, 2011
Molecular mechanisms underlying occult hepatitis B virus infection. Clin Microbiol Rev (2012) 1.30
Hepatitis C virus and other risk factors in hepatocellular carcinoma. Acta Virol (2012) 0.84
Hepatitis B virus Genotyping Among Patients With Cirrhosis. Jundishapur J Microbiol (2015) 0.79
Clinical significance of occult hepatitis B infection in progression of liver disease and carcinogenesis. J Cancer (2013) 0.78
Molecular mechanisms underlying HBsAg negativity in occult HBV infection. Eur J Clin Microbiol Infect Dis (2015) 0.77
Viral hepatitis markers in liver tissue in relation to serostatus in hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev (2013) 0.77
Occult hepatitis B virus infection in Egypt. World J Hepatol (2015) 0.76
Molecular characterization of occult hepatitis B virus infection in patients with end-stage liver disease in Colombia. PLoS One (2017) 0.75
Hepatocellular carcinoma. Lancet (2003) 22.54
Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology (2003) 4.72
Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"? Hepatology (2001) 4.28
Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol (2002) 3.83
Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med (1999) 3.08
Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology (2004) 2.87
Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis. Hepatology (1998) 2.52
Rapid and specific genotyping system for hepatitis B virus corresponding to six major genotypes by PCR using type-specific primers. J Clin Microbiol (2001) 2.42
A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology (1993) 2.41
Polymerase chain reaction to detect hepatitis B virus DNA and RNA sequences in primary liver cancers from patients negative for hepatitis B surface antigen. N Engl J Med (1990) 2.36
Hepatitis B virus DNA in patients with chronic liver disease and negative tests for hepatitis B surface antigen. N Engl J Med (1985) 2.29
Chronic hepatitis B. N Engl J Med (2002) 2.28
Frequency of HBV DNA detection in US blood donors testing positive for the presence of anti-HBc: implications for transfusion transmission and donor screening. Transfusion (2003) 2.00
Occult hepatitis B virus infection and its clinical implications. J Viral Hepat (2002) 1.82
Hepatitis B virus X protein induces lipogenic transcription factor SREBP1 and fatty acid synthase through the activation of nuclear receptor LXRalpha. Biochem J (2008) 1.69
Prevalence of naturally occurring surface gene variants of hepatitis B virus in nonimmunized surface antigen-negative Chinese carriers. Hepatology (2001) 1.61
Occult hepatitis B virus infection. Transfus Clin Biol (2004) 1.55
Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. Hepatology (2000) 1.49
Clinical impact of occult HBV infections. J Clin Virol (2005) 1.46
Occult hepatitis B virus after acute self-limited infection persisting for 30 years without sequence variation. J Hepatol (2000) 1.44
Serologically silent hepatitis B virus coinfection in patients with hepatitis C virus-associated chronic liver disease: clinical and virological significance. J Med Virol (1999) 1.40
High viral load is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Gastroenterol Hepatol (2004) 1.32
Detection of hepatitis B virus DNA by polymerase chain reaction in plasma of volunteer blood donors negative for hepatitis B surface antigen. J Infect Dis (1991) 1.31
Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy--pathogenesis and management. Rev Med Virol (2001) 1.23
High prevalence of occult hepatitis B in Baltimore injection drug users. Hepatology (2004) 1.23
Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies. J Viral Hepat (2004) 1.19
Phylogenetic analysis of new hepatitis B virus isolates from Nigeria supports endemicity of genotype E in West Africa. J Med Virol (2001) 1.14
Hepatitis B virus DNA in sera and liver tissue of HBsAg negative patients with chronic hepatitis C. J Hepatol (2000) 1.11
Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis B virus endemic area. J Hepatol (2005) 1.06
Occult HBV infection and YMDD variants in hemodialysis patients with chronic HCV infection. J Hepatol (2003) 1.01
Prevalence of hepatitis B and C in Egypt and Africa. Antivir Ther (1998) 1.00
Hepatitis B virus (HBV) genotypes in Egyptian pediatric cancer patients with acute and chronic active HBV infection. Virol J (2007) 0.99
Hepatitis B virus genotypes, phylogeny and occult infection in a region with a high incidence of hepatocellular carcinoma in China. World J Gastroenterol (2004) 0.98
Anti-HBc screening in Egyptian blood donors reduces the risk of hepatitis B virus transmission. Transfus Med (2008) 0.97
Genotyping of Tunisian hepatitis B virus isolates based on the sequencing of preS2 and S regions. Microbes Infect (2000) 0.95
Antibody to hepatitis B core antigen as a screening test for occult hepatitis B virus infection in Egyptian chronic hepatitis C patients. J Gastroenterol (2009) 0.94
The clinical features of chronic hepatitis C are not affected by the coexistence of hepatitis B virus DNA in patients negative for hepatitis B surface antigen. Intervirology (2000) 0.89
Geographic characterization of hepatitis virus infections, genotyping of hepatitis B virus, and p53 mutation in hepatocellular carcinoma analyzed by in situ detection of viral genomes from carcinoma tissues: comparison among six different countries. Jpn J Infect Dis (2003) 0.88
Fulminant hepatitis type B after chemotherapy in a serologically negative hepatitis B virus carrier with acute myelogenous leukemia. Int J Hematol (2001) 0.83
HBV genome integration and genetic instability in HBsAg-negative and anti-HCV-positive hepatocellular carcinoma in Japan. Cancer Lett (1997) 0.82
Overt and hidden coinfection with hepatitis B and C viruses in chronic liver disease and porphyria cutanea tarda. Acta Virol (2000) 0.80
Hepatitis B virus DNA detected by PCR in sera and liver tissues of Chinese patients with chronic liver diseases. Chin Med J (Engl) (1993) 0.79
[Detection of HBV-DNA from hepatocellular carcinoma by polymerase chain reaction]. Nihon Rinsho (1995) 0.78
Inapparent "wild-type" and "e-minus variant" HBV infection in patients with HCV-related chronic hepatitis. Liver (1994) 0.77
Hepatitis B virus (HBV) genotypes in Egyptian pediatric cancer patients with acute and chronic active HBV infection. Virol J (2007) 0.99
Doxorubicin toxicity can be ameliorated during antioxidant L-carnitine supplementation. Oxid Med Cell Longev (2010) 0.95
Thymoquinone supplementation attenuates cyclophosphamide-induced cardiotoxicity in rats. J Biochem Mol Toxicol (2010) 0.95
Seroprevalence of herpes simplex virus types 1 and 2, Epstein-Barr virus, and cytomegalovirus in children with acute lymphoblastic leukemia in Egypt. Saudi Med J (2006) 0.91
The possible role of cell cycle regulators in multistep process of HPV-associated cervical carcinoma. BMC Clin Pathol (2007) 0.88
The role of cyclins and cyclins inhibitors in the multistep process of HPV-associated cervical carcinoma. J Egypt Natl Canc Inst (2006) 0.88
Inhibition of gene expression of heart fatty acid binding protein and organic cation/carnitine transporter in doxorubicin cardiomyopathic rat model. Eur J Pharmacol (2010) 0.87
Molecular characteristics of extended-spectrum β-lactamase-producing Escherichia coli in Riyadh: emergence of CTX-M-15-producing E. coli ST131. Ann Clin Microbiol Antimicrob (2014) 0.86
Epstein-Barr virus and breast cancer: epidemiological and molecular study on Egyptian and Iraqi women. J Egypt Natl Canc Inst (2012) 0.86
MicroRNAs and metastasis-related gene expression in Egyptian breast cancer patients. Asian Pac J Cancer Prev (2012) 0.84
Desferrioxamine attenuates doxorubicin-induced acute cardiotoxicity through TFG-β/Smad p53 pathway in rat model. Oxid Med Cell Longev (2012) 0.84
Protective effect of rutin on the antioxidant genes expression in hypercholestrolemic male Westar rat. BMC Complement Altern Med (2013) 0.84
Management of cardiac fibrosis in diabetic rats; the role of peroxisome proliferator activated receptor gamma (PPAR-gamma) and calcium channel blockers (CCBs). Diabetol Metab Syndr (2011) 0.83
Genetic profile of Egyptian hepatocellular-carcinoma associated with hepatitis C virus Genotype 4 by 15 K cDNA microarray: preliminary study. BMC Res Notes (2008) 0.82
Molecular prognostic profile of Egyptian HCC cases infected with hepatitis C virus. Asian Pac J Cancer Prev (2012) 0.82
Characterization of chronic HCV infection-induced apoptosis. Comp Hepatol (2011) 0.81
The correlation between FHIT, P53 and MMR genes in human papillomavirus-associated cervical carcinoma. J Egypt Natl Canc Inst (2006) 0.81
Investigation into the seroprevalence of falcon herpesvirus antibodies in raptors in the UK using virus neutralization tests and different herpesvirus isolates. Avian Pathol (2004) 0.78
Downregulation of oxidative and nitrosative apoptotic signaling by L-carnitine in Ifosfamide-induced Fanconi syndrome rat model. Oxid Med Cell Longev (2012) 0.78
Inhibition of gene expression of organic cation/carnitine transporter and antioxidant enzymes in oxazaphosphorines-induced acute cardiomyopathic rat models. Oxid Med Cell Longev (2012) 0.77
Gene expression patterns in the hippocampus during the development and aging of Glud1 (Glutamate Dehydrogenase 1) transgenic and wild type mice. BMC Neurosci (2014) 0.77
Enhanced antibacterial effect of ceftriaxone sodium-loaded chitosan nanoparticles against intracellular Salmonella typhimurium. AAPS PharmSciTech (2012) 0.77
Inhibition of gene expression of carnitine palmitoyltransferase I and heart fatty acid binding protein in cyclophosphamide and ifosfamide-induced acute cardiotoxic rat models. Cardiovasc Toxicol (2014) 0.76
Human Papillomavirus Genotypes and Methylation of CADM1, PAX1, MAL and ADCYAP1 Genes in Epithelial Ovarian Cancer Patients Asian Pac J Cancer Prev (2017) 0.75
Inhibitory Effect of Ginseng on Breast Cancer Cell Line Growth Via Up-Regulation of Cyclin Dependent Kinase Inhibitor, p21 and p53 Asian Pac J Cancer Prev (2016) 0.75